Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study
Regular consumption of flavonoids may reduce the risk for CVD. However, the effects of individual flavonoids, for example, quercetin, remain unclear. The present study was undertaken to examine the effects of quercetin supplementation on blood pressure, lipid metabolism, markers of oxidative stress,...
Saved in:
| Published in | British journal of nutrition Vol. 102; no. 7; pp. 1065 - 1074 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cambridge, UK
Cambridge University Press
14.10.2009
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Regular consumption of flavonoids may reduce the risk for CVD. However, the effects of individual flavonoids, for example, quercetin, remain unclear. The present study was undertaken to examine the effects of quercetin supplementation on blood pressure, lipid metabolism, markers of oxidative stress, inflammation, and body composition in an at-risk population of ninety-three overweight or obese subjects aged 25–65 years with metabolic syndrome traits. Subjects were randomised to receive 150 mg quercetin/d in a double-blinded, placebo-controlled cross-over trial with 6-week treatment periods separated by a 5-week washout period. Mean fasting plasma quercetin concentrations increased from 71 to 269 nmol/l (P < 0·001) during quercetin treatment. In contrast to placebo, quercetin decreased systolic blood pressure (SBP) by 2·6 mmHg (P < 0·01) in the entire study group, by 2·9 mmHg (P < 0·01) in the subgroup of hypertensive subjects and by 3·7 mmHg (P < 0·001) in the subgroup of younger adults aged 25–50 years. Quercetin decreased serum HDL-cholesterol concentrations (P < 0·001), while total cholesterol, TAG and the LDL:HDL-cholesterol and TAG:HDL-cholesterol ratios were unaltered. Quercetin significantly decreased plasma concentrations of atherogenic oxidised LDL, but did not affect TNF-α and C-reactive protein when compared with placebo. Quercetin supplementation had no effects on nutritional status. Blood parameters of liver and kidney function, haematology and serum electrolytes did not reveal any adverse effects of quercetin. In conclusion, quercetin reduced SBP and plasma oxidised LDL concentrations in overweight subjects with a high-CVD risk phenotype. Our findings provide further evidence that quercetin may provide protection against CVD. |
|---|---|
| AbstractList | Regular consumption of flavonoids may reduce the risk for CVD. However, the effects of individual flavonoids, for example, quercetin, remain unclear. The present study was undertaken to examine the effects of quercetin supplementation on blood pressure, lipid metabolism, markers of oxidative stress, inflammation, and body composition in an at-risk population of ninety-three overweight or obese subjects aged 25-65 years with metabolic syndrome traits. Subjects were randomised to receive 150 mg quercetin/d in a double-blinded, placebo-controlled cross-over trial with 6-week treatment periods separated by a 5-week washout period. Mean fasting plasma quercetin concentrations increased from 71 to 269 nmol/l (P < 0.001) during quercetin treatment. In contrast to placebo, quercetin decreased systolic blood pressure (SBP) by 2.6 mmHg (P < 0.01) in the entire study group, by 2.9 mmHg (P < 0.01) in the subgroup of hypertensive subjects and by 3.7 mmHg (P < 0.001) in the subgroup of younger adults aged 25-50 years. Quercetin decreased serum HDL-cholesterol concentrations (P < 0.001), while total cholesterol, TAG and the LDL:HDL-cholesterol and TAG:HDL-cholesterol ratios were unaltered. Quercetin significantly decreased plasma concentrations of atherogenic oxidised LDL, but did not affect TNF-alpha and C-reactive protein when compared with placebo. Quercetin supplementation had no effects on nutritional status. Blood parameters of liver and kidney function, haematology and serum electrolytes did not reveal any adverse effects of quercetin. In conclusion, quercetin reduced SBP and plasma oxidised LDL concentrations in overweight subjects with a high-CVD risk phenotype. Our findings provide further evidence that quercetin may provide protection against CVD.Regular consumption of flavonoids may reduce the risk for CVD. However, the effects of individual flavonoids, for example, quercetin, remain unclear. The present study was undertaken to examine the effects of quercetin supplementation on blood pressure, lipid metabolism, markers of oxidative stress, inflammation, and body composition in an at-risk population of ninety-three overweight or obese subjects aged 25-65 years with metabolic syndrome traits. Subjects were randomised to receive 150 mg quercetin/d in a double-blinded, placebo-controlled cross-over trial with 6-week treatment periods separated by a 5-week washout period. Mean fasting plasma quercetin concentrations increased from 71 to 269 nmol/l (P < 0.001) during quercetin treatment. In contrast to placebo, quercetin decreased systolic blood pressure (SBP) by 2.6 mmHg (P < 0.01) in the entire study group, by 2.9 mmHg (P < 0.01) in the subgroup of hypertensive subjects and by 3.7 mmHg (P < 0.001) in the subgroup of younger adults aged 25-50 years. Quercetin decreased serum HDL-cholesterol concentrations (P < 0.001), while total cholesterol, TAG and the LDL:HDL-cholesterol and TAG:HDL-cholesterol ratios were unaltered. Quercetin significantly decreased plasma concentrations of atherogenic oxidised LDL, but did not affect TNF-alpha and C-reactive protein when compared with placebo. Quercetin supplementation had no effects on nutritional status. Blood parameters of liver and kidney function, haematology and serum electrolytes did not reveal any adverse effects of quercetin. In conclusion, quercetin reduced SBP and plasma oxidised LDL concentrations in overweight subjects with a high-CVD risk phenotype. Our findings provide further evidence that quercetin may provide protection against CVD. Regular consumption of flavonoids may reduce the risk for CVD. However, the effects of individual flavonoids, for example, quercetin, remain unclear. The present study was undertaken to examine the effects of quercetin supplementation on blood pressure, lipid metabolism, markers of oxidative stress, inflammation, and body composition in an at-risk population of ninety-three overweight or obese subjects aged 25-65 years with metabolic syndrome traits. Subjects were randomised to receive 150 mg quercetin/d in a double-blinded, placebo-controlled cross-over trial with 6-week treatment periods separated by a 5-week washout period. Mean fasting plasma quercetin concentrations increased from 71 to 269 nmol/l (P < 0.001) during quercetin treatment. In contrast to placebo, quercetin decreased systolic blood pressure (SBP) by 2.6 mmHg (P < 0.01) in the entire study group, by 2.9 mmHg (P < 0.01) in the subgroup of hypertensive subjects and by 3.7 mmHg (P < 0.001) in the subgroup of younger adults aged 25-50 years. Quercetin decreased serum HDL-cholesterol concentrations (P < 0.001), while total cholesterol, TAG and the LDL:HDL-cholesterol and TAG:HDL-cholesterol ratios were unaltered. Quercetin significantly decreased plasma concentrations of atherogenic oxidised LDL, but did not affect TNF-alpha and C-reactive protein when compared with placebo. Quercetin supplementation had no effects on nutritional status. Blood parameters of liver and kidney function, haematology and serum electrolytes did not reveal any adverse effects of quercetin. In conclusion, quercetin reduced SBP and plasma oxidised LDL concentrations in overweight subjects with a high-CVD risk phenotype. Our findings provide further evidence that quercetin may provide protection against CVD. Regular consumption of flavonoids may reduce the risk for CVD. However, the effects of individual flavonoids, for example, quercetin, remain unclear. The present study was undertaken to examine the effects of quercetin supplementation on blood pressure, lipid metabolism, markers of oxidative stress, inflammation, and body composition in an at-risk population of ninety-three overweight or obese subjects aged 25–65 years with metabolic syndrome traits. Subjects were randomised to receive 150 mg quercetin/d in a double-blinded, placebo-controlled cross-over trial with 6-week treatment periods separated by a 5-week washout period. Mean fasting plasma quercetin concentrations increased from 71 to 269 nmol/l (P < 0·001) during quercetin treatment. In contrast to placebo, quercetin decreased systolic blood pressure (SBP) by 2·6 mmHg (P < 0·01) in the entire study group, by 2·9 mmHg (P < 0·01) in the subgroup of hypertensive subjects and by 3·7 mmHg (P < 0·001) in the subgroup of younger adults aged 25–50 years. Quercetin decreased serum HDL-cholesterol concentrations (P < 0·001), while total cholesterol, TAG and the LDL:HDL-cholesterol and TAG:HDL-cholesterol ratios were unaltered. Quercetin significantly decreased plasma concentrations of atherogenic oxidised LDL, but did not affect TNF-α and C-reactive protein when compared with placebo. Quercetin supplementation had no effects on nutritional status. Blood parameters of liver and kidney function, haematology and serum electrolytes did not reveal any adverse effects of quercetin. In conclusion, quercetin reduced SBP and plasma oxidised LDL concentrations in overweight subjects with a high-CVD risk phenotype. Our findings provide further evidence that quercetin may provide protection against CVD. Regular consumption of flavonoids may reduce the risk for CVD. However, the effects of individual flavonoids, for example, quercetin, remain unclear. The present study was undertaken to examine the effects of quercetin supplementation on blood pressure, lipid metabolism, markers of oxidative stress, inflammation, and body composition in an at-risk population of ninety-three overweight or obese subjects aged 25-65 years with metabolic syndrome traits. Subjects were randomised to receive 150mg quercetin/d in a double-blinded, placebo-controlled cross-over trial with 6-week treatment periods separated by a 5-week washout period. Mean fasting plasma quercetin concentrations increased from 71 to 269nmol/l (P<0.001) during quercetin treatment. In contrast to placebo, quercetin decreased systolic blood pressure (SBP) by 2.6mmHg (P<0.01) in the entire study group, by 2.9mmHg (P<0.01) in the subgroup of hypertensive subjects and by 3.7mmHg (P<0.001) in the subgroup of younger adults aged 25-50 years. Quercetin decreased serum HDL-cholesterol concentrations (P<0.001), while total cholesterol, TAG and the LDL:HDL-cholesterol and TAG:HDL-cholesterol ratios were unaltered. Quercetin significantly decreased plasma concentrations of atherogenic oxidised LDL, but did not affect TNF-a and C-reactive protein when compared with placebo. Quercetin supplementation had no effects on nutritional status. Blood parameters of liver and kidney function, haematology and serum electrolytes did not reveal any adverse effects of quercetin. In conclusion, quercetin reduced SBP and plasma oxidised LDL concentrations in overweight subjects with a high-CVD risk phenotype. Our findings provide further evidence that quercetin may provide protection against CVD. Regular consumption of flavonoids may reduce the risk for CVD. However, the effects of individual flavonoids, for example, quercetin, remain unclear. The present study was undertaken to examine the effects of quercetin supplementation on blood pressure, lipid metabolism, markers of oxidative stress, inflammation, and body composition in an at-risk population of ninety-three overweight or obese subjects aged 25–65 years with metabolic syndrome traits. Subjects were randomised to receive 150 mg quercetin/d in a double-blinded, placebo-controlled cross-over trial with 6-week treatment periods separated by a 5-week washout period. Mean fasting plasma quercetin concentrations increased from 71 to 269 nmol/l (P < 0·001) during quercetin treatment. In contrast to placebo, quercetin decreased systolic blood pressure (SBP) by 2·6 mmHg (P < 0·01) in the entire study group, by 2·9 mmHg (P < 0·01) in the subgroup of hypertensive subjects and by 3·7 mmHg (P < 0·001) in the subgroup of younger adults aged 25–50 years. Quercetin decreased serum HDL-cholesterol concentrations (P < 0·001), while total cholesterol, TAG and the LDL:HDL-cholesterol and TAG:HDL-cholesterol ratios were unaltered. Quercetin significantly decreased plasma concentrations of atherogenic oxidised LDL, but did not affect TNF-α and C-reactive protein when compared with placebo. Quercetin supplementation had no effects on nutritional status. Blood parameters of liver and kidney function, haematology and serum electrolytes did not reveal any adverse effects of quercetin. In conclusion, quercetin reduced SBP and plasma oxidised LDL concentrations in overweight subjects with a high-CVD risk phenotype. Our findings provide further evidence that quercetin may provide protection against CVD. Regular consumption of flavonoids may reduce the risk for CVD. However, the effects of individual flavonoids, for example, quercetin, remain unclear. The present study was undertaken to examine the effects of quercetin supplementation on blood pressure, lipid metabolism, markers of oxidative stress, inflammation, and body composition in an at-risk population of ninety-three overweight or obese subjects aged 25–65 years with metabolic syndrome traits. Subjects were randomised to receive 150 mg quercetin/d in a double-blinded, placebo-controlled cross-over trial with 6-week treatment periods separated by a 5-week washout period. Mean fasting plasma quercetin concentrations increased from 71 to 269 nmol/l ( P < 0·001) during quercetin treatment. In contrast to placebo, quercetin decreased systolic blood pressure (SBP) by 2·6 mmHg ( P < 0·01) in the entire study group, by 2·9 mmHg ( P < 0·01) in the subgroup of hypertensive subjects and by 3·7 mmHg ( P < 0·001) in the subgroup of younger adults aged 25–50 years. Quercetin decreased serum HDL-cholesterol concentrations ( P < 0·001), while total cholesterol, TAG and the LDL:HDL-cholesterol and TAG:HDL-cholesterol ratios were unaltered. Quercetin significantly decreased plasma concentrations of atherogenic oxidised LDL, but did not affect TNF-α and C-reactive protein when compared with placebo. Quercetin supplementation had no effects on nutritional status. Blood parameters of liver and kidney function, haematology and serum electrolytes did not reveal any adverse effects of quercetin. In conclusion, quercetin reduced SBP and plasma oxidised LDL concentrations in overweight subjects with a high-CVD risk phenotype. Our findings provide further evidence that quercetin may provide protection against CVD. Regular consumption of flavonoids may reduce the risk for CVD. However, the effects of individual flavonoids, for example, quercetin, remain unclear. The present study was undertaken to examine the effects of quercetin supplementation on blood pressure, lipid metabolism, markers of oxidative stress, inflammation, and body composition in an at-risk population of ninety-three overweight or obese subjects aged 25-65 years with metabolic syndrome traits. Subjects were randomised to receive 150 mg quercetin/d in a double-blinded, placebo-controlled cross-over trial with 6-week treatment periods separated by a 5-week washout period. Mean fasting plasma quercetin concentrations increased from 71 to 269 nmol/l (P < 0·001) during quercetin treatment. In contrast to placebo, quercetin decreased systolic blood pressure (SBP) by 2·6 mmHg (P < 0·01) in the entire study group, by 2·9 mmHg (P < 0·01) in the subgroup of hypertensive subjects and by 3·7 mmHg (P < 0·001) in the subgroup of younger adults aged 25-50 years. Quercetin decreased serum HDL-cholesterol concentrations (P < 0·001), while total cholesterol, TAG and the LDL:HDL-cholesterol and TAG:HDL-cholesterol ratios were unaltered. Quercetin significantly decreased plasma concentrations of atherogenic oxidised LDL, but did not affect TNF-α and C-reactive protein when compared with placebo. Quercetin supplementation had no effects on nutritional status. Blood parameters of liver and kidney function, haematology and serum electrolytes did not reveal any adverse effects of quercetin. In conclusion, quercetin reduced SBP and plasma oxidised LDL concentrations in overweight subjects with a high-CVD risk phenotype. Our findings provide further evidence that quercetin may provide protection against CVD. [PUBLICATION ABSTRACT] |
| Author | Seiberl, Jasmin Frank, Jan Schrezenmeir, Jürgen Settler, Uta Kürbitz, Claudia Wagner, Anika E. Plachta-Danielzik, Sandra Wolffram, Siegfried Bosy-Westphal, Anja Rimbach, Gerald Müller, Manfred J. Egert, Sarah |
| Author_xml | – sequence: 1 givenname: Sarah surname: Egert fullname: Egert, Sarah organization: 1Institute of Human Nutrition and Food Science, Department of Human Nutrition, Christian-Albrechts-University Kiel, 24105Kiel, Germany – sequence: 2 givenname: Anja surname: Bosy-Westphal fullname: Bosy-Westphal, Anja organization: 1Institute of Human Nutrition and Food Science, Department of Human Nutrition, Christian-Albrechts-University Kiel, 24105Kiel, Germany – sequence: 3 givenname: Jasmin surname: Seiberl fullname: Seiberl, Jasmin organization: 1Institute of Human Nutrition and Food Science, Department of Human Nutrition, Christian-Albrechts-University Kiel, 24105Kiel, Germany – sequence: 4 givenname: Claudia surname: Kürbitz fullname: Kürbitz, Claudia organization: 1Institute of Human Nutrition and Food Science, Department of Human Nutrition, Christian-Albrechts-University Kiel, 24105Kiel, Germany – sequence: 5 givenname: Uta surname: Settler fullname: Settler, Uta organization: 1Institute of Human Nutrition and Food Science, Department of Human Nutrition, Christian-Albrechts-University Kiel, 24105Kiel, Germany – sequence: 6 givenname: Sandra surname: Plachta-Danielzik fullname: Plachta-Danielzik, Sandra organization: 1Institute of Human Nutrition and Food Science, Department of Human Nutrition, Christian-Albrechts-University Kiel, 24105Kiel, Germany – sequence: 7 givenname: Anika E. surname: Wagner fullname: Wagner, Anika E. organization: 2Institute of Human Nutrition and Food Science, Department of Food Science, Christian-Albrechts-University Kiel, 24118Kiel, Germany – sequence: 8 givenname: Jan surname: Frank fullname: Frank, Jan organization: 2Institute of Human Nutrition and Food Science, Department of Food Science, Christian-Albrechts-University Kiel, 24118Kiel, Germany – sequence: 9 givenname: Jürgen surname: Schrezenmeir fullname: Schrezenmeir, Jürgen organization: 3Max Rubner-Institute, Federal Research Institute of Nutrition and Food, 24103Kiel, Germany – sequence: 10 givenname: Gerald surname: Rimbach fullname: Rimbach, Gerald organization: 2Institute of Human Nutrition and Food Science, Department of Food Science, Christian-Albrechts-University Kiel, 24118Kiel, Germany – sequence: 11 givenname: Siegfried surname: Wolffram fullname: Wolffram, Siegfried organization: 4Institute of Animal Nutrition, Physiology and Metabolism, Christian-Albrechts-University Kiel, 24118Kiel, Germany – sequence: 12 givenname: Manfred J. surname: Müller fullname: Müller, Manfred J. email: mmueller@nutrfoodsc.uni-kiel.de organization: 1Institute of Human Nutrition and Food Science, Department of Human Nutrition, Christian-Albrechts-University Kiel, 24105Kiel, Germany |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21984523$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19402938$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkt9PFDEQxzcGIwf6B_iiDYn64mrbbbe7vhmiYMQoQXzddNu5u0KvPdsucP-vf4hd7oQEIz41M_OZH5357hRbzjsoiqcEvyGYiLcnGGNBCOO4rXhLqHhQTAgTvKR1TbeKyRgux_h2sRPjWTYbgttHxTZpGaZt1UyKX8cDBAXJOBRADwoiiquYvDUK9dZ7jZYBYhwCIOmyYWVcSOSvjDYRNLL-stTgokkrZM3SL4NPkGsp7xS4FGQy3kWUPf4CwiWY2TyhOPRnoFJElybNkUTz7C2VDNr4CxnVYGVAY3kZAQUTz9FyDs6n1RLeZVr7obdQ9tY4Dfr1OJKC3pe5ZQre2jyVCj7GcuyIYhr06nHxcCpthCebd7c4_fjh-_5hefT14NP--6NS8bpNJQdQnDeYtb2a9s0UJOeUS0KZqmgNSgneEIoFrZlsFFAlNeFEyoor2lQUV7vFq3XdvIafA8TULUxUYK104IfYCcZqUjUV-T9ZMVxTIUby5b0kq5nIx6wzuHcHPPNDcPm_Hc1NactYm6FnG2joF6C7ZTALGVbdH0Fk4MUGyJeQdhqkUybecJS0DeO0yhxZc9e7DjC9LYW7UZzdX-LMOeJOjjLpWiFZKMbem1muM01McHXTSobzrhaV4F19cNz9aA7ZZ3r4rfuS-edrfip9J2dZRN3pCcWkwqRuBRM0E9VmFrnog9EzuF3Xv-f4DVTcFEE |
| CODEN | BJNUAV |
| CitedBy_id | crossref_primary_10_1016_j_jfda_2016_12_015 crossref_primary_10_1017_S0007114511004193 crossref_primary_10_3945_an_111_001271 crossref_primary_10_3389_fnut_2024_1393575 crossref_primary_10_1007_s00394_018_1695_0 crossref_primary_10_1016_j_nut_2018_06_012 crossref_primary_10_2174_1871530319666190206225034 crossref_primary_10_1016_j_cpcardiol_2022_101350 crossref_primary_10_1111_nure_12152 crossref_primary_10_1016_j_abb_2010_06_036 crossref_primary_10_1071_RD14155 crossref_primary_10_3390_nu10121912 crossref_primary_10_1038_nutd_2017_34 crossref_primary_10_1016_j_indcrop_2023_116564 crossref_primary_10_2174_1381612825666190513095352 crossref_primary_10_1016_j_jep_2019_112358 crossref_primary_10_3390_nu14235051 crossref_primary_10_1007_s11130_020_00832_0 crossref_primary_10_1007_s10735_023_10134_9 crossref_primary_10_3390_molecules25092099 crossref_primary_10_1007_s10924_025_03552_1 crossref_primary_10_1038_ejcn_2010_91 crossref_primary_10_1016_j_fshw_2022_07_013 crossref_primary_10_1152_japplphysiol_00292_2019 crossref_primary_10_3390_molecules27207110 crossref_primary_10_1002_mnfr_201901035 crossref_primary_10_1016_j_fct_2018_10_042 crossref_primary_10_3390_molecules28052387 crossref_primary_10_1017_S0007114512003972 crossref_primary_10_3390_nu11081805 crossref_primary_10_4141_cjps2012_310 crossref_primary_10_1093_jpp_rgab093 crossref_primary_10_1089_jmf_2018_0193 crossref_primary_10_3390_nu7042345 crossref_primary_10_1017_S0007114515005310 crossref_primary_10_1177_2040622311430006 crossref_primary_10_1080_87559129_2019_1573432 crossref_primary_10_3389_fimmu_2021_606069 crossref_primary_10_5937_AASer2050113U crossref_primary_10_1016_j_bcp_2011_08_010 crossref_primary_10_1016_j_tifs_2017_04_001 crossref_primary_10_1080_09637486_2019_1627515 crossref_primary_10_14710_jnc_v11i1_32573 crossref_primary_10_3390_ijms17060921 crossref_primary_10_1016_j_clnu_2021_04_047 crossref_primary_10_1016_j_jnutbio_2019_108339 crossref_primary_10_1016_j_lfs_2021_119910 crossref_primary_10_1161_HYPERTENSIONAHA_115_06497 crossref_primary_10_1080_10408398_2023_2286475 crossref_primary_10_3945_ajcn_111_029330 crossref_primary_10_3390_foods12173262 crossref_primary_10_1016_j_clnu_2019_04_003 crossref_primary_10_1021_acsomega_0c01818 crossref_primary_10_1007_s40256_014_0068_1 crossref_primary_10_1016_j_jff_2024_106175 crossref_primary_10_1007_s00394_012_0343_3 crossref_primary_10_3390_medicines6040107 crossref_primary_10_1016_j_phymed_2015_10_018 crossref_primary_10_1161_JAHA_118_010977 crossref_primary_10_1371_journal_pone_0016200 crossref_primary_10_1007_s10517_022_05642_9 crossref_primary_10_1371_journal_pone_0076210 crossref_primary_10_1002_bmc_4016 crossref_primary_10_3390_ph3010237 crossref_primary_10_1155_2018_1049234 crossref_primary_10_1016_j_rvsc_2018_01_006 crossref_primary_10_1155_2019_8267234 crossref_primary_10_3390_biom15010151 crossref_primary_10_1080_10408398_2022_2067825 crossref_primary_10_1017_S0029665120006928 crossref_primary_10_1590_fst_122821 crossref_primary_10_1039_C8FO01997E crossref_primary_10_1161_HYPERTENSIONAHA_120_14473 crossref_primary_10_1016_j_jff_2019_03_011 crossref_primary_10_1016_j_vph_2012_09_002 crossref_primary_10_3390_endocrines3020023 crossref_primary_10_2174_1381612823666170329142936 crossref_primary_10_3390_nu10081120 crossref_primary_10_1016_j_ucl_2011_05_003 crossref_primary_10_1002_ptr_8168 crossref_primary_10_1093_nutrit_nuz071 crossref_primary_10_1016_j_jff_2020_104132 crossref_primary_10_3390_ijms22157893 crossref_primary_10_1371_journal_pone_0032673 crossref_primary_10_1016_j_nutres_2011_06_006 crossref_primary_10_1080_10408398_2021_1927977 crossref_primary_10_3390_ijms22116110 crossref_primary_10_1016_j_heliyon_2020_e03803 crossref_primary_10_2174_0109298673266672231121173432 crossref_primary_10_1007_s11694_020_00704_w crossref_primary_10_1017_S0007114512000669 crossref_primary_10_3390_foods11091232 crossref_primary_10_3390_molecules25030762 crossref_primary_10_3389_fcvm_2023_1203713 crossref_primary_10_1007_s00394_019_02069_3 crossref_primary_10_3390_nu13051480 crossref_primary_10_3390_ijms20194957 crossref_primary_10_1016_j_cropro_2012_03_009 crossref_primary_10_1017_S0029665116000720 crossref_primary_10_1016_j_ejmech_2018_06_053 crossref_primary_10_1089_jmf_2023_K_0067 crossref_primary_10_1016_j_biopha_2021_112120 crossref_primary_10_1080_10408398_2021_1983765 crossref_primary_10_3390_ijms161025168 crossref_primary_10_1007_s00204_014_1330_7 crossref_primary_10_3390_nu8030159 crossref_primary_10_3390_ijms23136939 crossref_primary_10_3390_molecules23040877 crossref_primary_10_1002_mnfr_201200721 crossref_primary_10_1016_j_ejmech_2018_10_020 crossref_primary_10_1039_D3FO01004J crossref_primary_10_1111_ijfs_17043 crossref_primary_10_1080_10590501_2013_763575 crossref_primary_10_1016_j_yexcr_2015_10_013 crossref_primary_10_3390_metabo14030146 crossref_primary_10_1038_ejcn_2010_135 crossref_primary_10_3109_10715760903407293 crossref_primary_10_1016_j_numecd_2011_05_001 crossref_primary_10_1017_S0007114512003571 crossref_primary_10_1016_j_freeradbiomed_2017_05_003 crossref_primary_10_1186_s13148_015_0095_z crossref_primary_10_1016_j_ijpharm_2019_118983 crossref_primary_10_3390_cancers15153884 crossref_primary_10_1016_j_jsps_2022_04_013 crossref_primary_10_1039_c0fo00103a crossref_primary_10_3390_molecules25010187 crossref_primary_10_3390_nu17071118 crossref_primary_10_1016_j_phymed_2021_153736 crossref_primary_10_1038_s41397_019_0082_4 crossref_primary_10_5937_Galmed2307046B crossref_primary_10_1017_S000711451000156X crossref_primary_10_1002_mnfr_201700447 crossref_primary_10_1017_S0007114511003242 crossref_primary_10_1017_S0029665112000249 crossref_primary_10_1002_14651858_CD009128_pub3 crossref_primary_10_1016_j_fbp_2017_02_008 crossref_primary_10_3109_10641963_2013_783048 crossref_primary_10_1016_j_nutres_2017_10_017 crossref_primary_10_1186_s12944_020_01357_w crossref_primary_10_1002_ptr_7144 crossref_primary_10_3390_ijms23010183 crossref_primary_10_1002_ptr_8238 crossref_primary_10_1007_s00394_011_0243_y crossref_primary_10_1155_2014_297293 crossref_primary_10_3390_life13030753 crossref_primary_10_3390_ijms21228706 crossref_primary_10_3945_jn_109_117655 crossref_primary_10_1155_2018_7421489 crossref_primary_10_1002_ptr_6166 crossref_primary_10_1016_j_phanu_2020_100250 crossref_primary_10_2174_1573399819666230427095200 crossref_primary_10_3390_molecules24234259 crossref_primary_10_3945_an_116_013623 crossref_primary_10_1371_journal_pone_0091571 crossref_primary_10_3390_agriculture13051039 crossref_primary_10_1080_10408398_2018_1518895 crossref_primary_10_1038_ismej_2012_141 crossref_primary_10_3390_nu7125519 crossref_primary_10_1089_rej_2011_1242 crossref_primary_10_1016_j_heliyon_2023_e23474 crossref_primary_10_1007_s10068_016_0271_8 crossref_primary_10_1007_s10953_016_0506_6 crossref_primary_10_3390_agriculture11090872 crossref_primary_10_1002_ptr_7002 crossref_primary_10_1007_s00394_016_1185_1 crossref_primary_10_1007_s42991_023_00386_z crossref_primary_10_3389_fnut_2024_1452374 crossref_primary_10_1016_j_jsbmb_2020_105795 crossref_primary_10_1136_bmjresp_2018_000392 crossref_primary_10_1089_regen_2021_0021 crossref_primary_10_5402_2013_581651 crossref_primary_10_1016_j_vph_2018_08_008 crossref_primary_10_3390_nu15092231 crossref_primary_10_3389_fnut_2022_974530 crossref_primary_10_1007_s10787_021_00902_y crossref_primary_10_1016_j_jada_2011_01_013 crossref_primary_10_1016_j_ctim_2019_05_027 crossref_primary_10_1002_mnfr_201200619 crossref_primary_10_1371_journal_pone_0266689 crossref_primary_10_3390_ijms21176448 crossref_primary_10_1016_j_jnutbio_2017_01_006 crossref_primary_10_1016_j_jff_2021_104811 crossref_primary_10_29105_respyn20_1_3 crossref_primary_10_1016_j_jfca_2017_04_006 crossref_primary_10_22141_2224_0721_20_6_2024_1439 crossref_primary_10_1038_ijo_2010_272 crossref_primary_10_1155_2017_1750306 crossref_primary_10_1007_s12011_021_02729_8 crossref_primary_10_15407_dopovidi2014_07_165 crossref_primary_10_1021_jf402511c crossref_primary_10_3390_nu5103779 crossref_primary_10_1007_s00394_015_1084_x crossref_primary_10_1080_08916934_2018_1442828 crossref_primary_10_4162_nrp_2021_15_4_444 crossref_primary_10_3892_mmr_2015_4340 crossref_primary_10_1002_mnfr_201700772 crossref_primary_10_3390_nu15040854 crossref_primary_10_1007_s11883_013_0368_y crossref_primary_10_3390_ijms10094168 crossref_primary_10_1016_j_prmcm_2024_100361 crossref_primary_10_1016_j_canlet_2014_02_008 crossref_primary_10_1016_j_nutres_2012_06_018 crossref_primary_10_3945_jn_114_203190 crossref_primary_10_3892_etm_2015_2713 crossref_primary_10_1021_jf500916d crossref_primary_10_1038_ejcn_2017_55 crossref_primary_10_1155_2012_906252 crossref_primary_10_3390_ijms24087146 crossref_primary_10_1002_ptr_8428 crossref_primary_10_3892_mmr_2016_6054 crossref_primary_10_1016_j_juro_2011_04_063 crossref_primary_10_1007_s00217_023_04368_w crossref_primary_10_1016_j_clnesp_2023_06_008 crossref_primary_10_1111_1750_3841_14285 crossref_primary_10_1002_adfm_202300261 crossref_primary_10_12717_DR_2013_17_1_037 crossref_primary_10_1002_ptr_7564 crossref_primary_10_3892_ijmm_2017_2907 crossref_primary_10_1017_S0007114515002950 crossref_primary_10_3945_jn_112_165274 crossref_primary_10_3109_09637486_2011_649250 crossref_primary_10_1093_nutrit_nuu014 crossref_primary_10_1016_j_pharep_2017_07_002 crossref_primary_10_7759_cureus_58219 crossref_primary_10_3390_molecules27144476 crossref_primary_10_3390_ph15081019 crossref_primary_10_2503_hrj_17_359 crossref_primary_10_2215_CJN_02020220 crossref_primary_10_1080_10408398_2012_656770 crossref_primary_10_1002_ptr_7436 crossref_primary_10_1096_fj_11_180935 crossref_primary_10_1016_j_tifs_2016_07_004 crossref_primary_10_1111_bcpt_14113 crossref_primary_10_2174_0929867326666181220094721 crossref_primary_10_1016_j_nut_2014_03_032 crossref_primary_10_3390_cosmetics10060149 crossref_primary_10_3389_fnut_2024_1409339 crossref_primary_10_3109_13880209_2014_1001403 crossref_primary_10_1016_j_jnutbio_2010_02_008 crossref_primary_10_1080_10408398_2014_948609 crossref_primary_10_3136_fstr_26_167 crossref_primary_10_1038_ejcn_2015_88 crossref_primary_10_1111_obr_12409 crossref_primary_10_1111_1753_0407_70014 crossref_primary_10_1016_j_jep_2021_114603 crossref_primary_10_1016_j_prenap_2025_100206 crossref_primary_10_1002_ptr_6334 crossref_primary_10_1016_j_bioorg_2017_07_018 crossref_primary_10_1089_act_2018_29197_mho crossref_primary_10_3390_antiox11091803 crossref_primary_10_3390_antiox12020258 crossref_primary_10_1007_s11101_021_09755_3 crossref_primary_10_3390_molecules22020209 crossref_primary_10_15430_JCP_2015_20_3_202 crossref_primary_10_1016_j_biopha_2023_115274 crossref_primary_10_1093_nutrit_nuv048 crossref_primary_10_4162_nrp_2024_18_1_33 crossref_primary_10_1016_j_ejmech_2023_116075 crossref_primary_10_1039_C7FO00975E crossref_primary_10_5402_2011_397136 crossref_primary_10_3390_molecules24193626 crossref_primary_10_1007_s13205_018_1153_y crossref_primary_10_2174_0929867327666200713184138 crossref_primary_10_3390_app14041324 crossref_primary_10_1080_1028415X_2023_2298098 crossref_primary_10_1016_j_jnutbio_2014_10_008 crossref_primary_10_1039_c2fo10268d crossref_primary_10_3390_foods10010045 crossref_primary_10_3390_antiox12020281 crossref_primary_10_1016_j_autneu_2020_102759 crossref_primary_10_1111_jpn_12584 crossref_primary_10_1002_mnfr_201500761 crossref_primary_10_1007_s00210_014_0995_z crossref_primary_10_3945_ajcn_113_073106 crossref_primary_10_1016_j_arabjc_2023_104881 crossref_primary_10_1002_chem_202001956 crossref_primary_10_3390_ph16111631 crossref_primary_10_1039_C9NP00057G crossref_primary_10_1007_s40200_022_00987_4 crossref_primary_10_1016_j_nut_2014_02_022 crossref_primary_10_1016_j_nut_2010_10_013 crossref_primary_10_1016_j_biopha_2024_116860 crossref_primary_10_1002_mnfr_201500751 crossref_primary_10_3109_13880209_2014_950387 crossref_primary_10_3389_fphar_2021_779652 crossref_primary_10_1039_D2FO00912A crossref_primary_10_3389_fragi_2024_1495029 crossref_primary_10_3945_ajcn_113_074237 crossref_primary_10_1016_j_hermed_2021_100525 crossref_primary_10_1016_j_jep_2020_113270 crossref_primary_10_1016_j_jep_2021_113791 crossref_primary_10_2174_1566524023666230320103429 crossref_primary_10_3945_jn_111_157263 crossref_primary_10_1039_D1FO02033A crossref_primary_10_1021_acs_jafc_8b03003 crossref_primary_10_1016_j_fct_2013_11_002 crossref_primary_10_1016_j_phrs_2022_106414 crossref_primary_10_1007_s12035_016_0203_x crossref_primary_10_1186_s42269_022_00958_y crossref_primary_10_1016_j_ejmcr_2025_100256 crossref_primary_10_3390_nu9020117 crossref_primary_10_3390_nu9020111 crossref_primary_10_1017_S0007114513000780 crossref_primary_10_4103_2225_4110_129562 crossref_primary_10_1016_j_coph_2019_04_014 crossref_primary_10_1055_s_0044_1791559 crossref_primary_10_1111_jnc_14033 crossref_primary_10_2174_2589977515666230822114324 crossref_primary_10_1161_ATVBAHA_112_300260 crossref_primary_10_1111_j_1467_3010_2010_01822_x crossref_primary_10_1177_17534666231170800 crossref_primary_10_1007_s00394_014_0673_4 crossref_primary_10_3390_ijms25158481 crossref_primary_10_1017_S0007114511002613 crossref_primary_10_1002_ejlt_201600077 crossref_primary_10_1016_j_cmet_2019_01_018 crossref_primary_10_1186_s41110_020_00118_0 crossref_primary_10_1016_j_lfs_2014_06_014 crossref_primary_10_1097_MD_0000000000033636 crossref_primary_10_3945_ajcn_116_131268 crossref_primary_10_1007_s40265_022_01743_x crossref_primary_10_1111_ijfs_14459 crossref_primary_10_1016_j_phymed_2022_154348 crossref_primary_10_1016_j_bcp_2012_03_005 crossref_primary_10_1111_1750_3841_12056 crossref_primary_10_1111_1750_3841_14473 crossref_primary_10_1002_fsn3_3499 crossref_primary_10_1007_s10557_020_07100_y crossref_primary_10_3136_fstr_FSTR_D_21_00264 crossref_primary_10_1016_j_toxlet_2013_09_004 crossref_primary_10_1080_10408398_2014_952399 crossref_primary_10_1080_07315724_2017_1394237 crossref_primary_10_3945_ajcn_114_098590 crossref_primary_10_1016_j_foodres_2021_110488 crossref_primary_10_4236_fns_2014_511117 crossref_primary_10_1016_j_biopha_2020_110205 crossref_primary_10_3390_biom14020221 crossref_primary_10_1111_nyas_13361 crossref_primary_10_1007_s00204_024_03850_y crossref_primary_10_1002_biof_1728 crossref_primary_10_1039_C5RA22840A crossref_primary_10_3390_nu10020120 crossref_primary_10_3389_fcvm_2021_658400 crossref_primary_10_1039_C5FO00155B crossref_primary_10_1080_13510002_2023_2289740 crossref_primary_10_4162_nrp_2011_5_1_28 crossref_primary_10_1186_s42779_024_00248_0 crossref_primary_10_3390_ph17101354 crossref_primary_10_1007_s00421_010_1674_5 crossref_primary_10_1016_j_tjnut_2024_05_005 crossref_primary_10_1021_jf304595p crossref_primary_10_1016_j_bcp_2017_03_021 crossref_primary_10_1017_S0007114519002137 crossref_primary_10_1016_j_ejps_2014_01_003 crossref_primary_10_1016_j_nutres_2014_05_002 crossref_primary_10_1016_j_fitote_2013_03_016 crossref_primary_10_1371_journal_pone_0264802 crossref_primary_10_1093_eurheartj_ehw303 crossref_primary_10_3390_foods11162524 crossref_primary_10_1039_D1FO02782D crossref_primary_10_1021_acs_iecr_8b03060 crossref_primary_10_15407_dopovidi2014_03_153 crossref_primary_10_1186_s40779_022_00389_w crossref_primary_10_3389_fcell_2020_613006 crossref_primary_10_1002_ptr_6955 crossref_primary_10_1007_s13668_015_0137_3 crossref_primary_10_1017_S0007114510000711 crossref_primary_10_1016_j_jep_2024_118967 crossref_primary_10_1080_10408398_2022_2049202 crossref_primary_10_1002_mnfr_201200178 crossref_primary_10_3390_molecules27217222 crossref_primary_10_1124_jpet_112_196147 crossref_primary_10_3390_nu11102288 crossref_primary_10_1080_10408398_2019_1604491 crossref_primary_10_1161_JAHA_115_002713 crossref_primary_10_29252_nfsr_7_2_21 crossref_primary_10_1002_mnfr_201600557 crossref_primary_10_3390_ijms25084292 crossref_primary_10_1016_j_pharmthera_2019_02_013 crossref_primary_10_3390_ijms23158344 crossref_primary_10_1007_s00394_016_1267_0 crossref_primary_10_3390_plants11192623 crossref_primary_10_1111_j_1742_7843_2010_00583_x crossref_primary_10_1016_j_clindermatol_2018_03_011 crossref_primary_10_2217_fvl_2023_0190 crossref_primary_10_3390_nu14091973 crossref_primary_10_1097_01_NPR_0000731560_23509_ff crossref_primary_10_3390_nu9070773 crossref_primary_10_1155_2020_8825387 crossref_primary_10_3109_09637486_2013_787397 crossref_primary_10_1111_jch_12211 |
| Cites_doi | 10.1038/oby.2008.315 10.1093/ajcn/88.4.1018 10.1093/ajcn/70.6.1040 10.1074/jbc.M706571200 10.1093/ajcn/88.1.38 10.1017/S1462399403006732 10.1007/PL00007376 10.1016/S0022-2275(20)32358-0 10.1128/CVI.13.3.319-328.2006 10.1038/sj.ijo.0802756 10.1074/jbc.M606804200 10.1093/jn/135.9.2257 10.1001/jama.289.19.2560 10.1021/jf8003042 10.2337/diabetes.53.4.1068 10.1093/jn/138.9.1615 10.1093/jn/138.8.1417 10.1093/ajcn/81.1.122 10.1093/ajcn/78.6.1135 10.1002/sim.4780060806 10.1016/j.nut.2008.03.023 10.1007/BF01617836 10.1093/ajcn/76.3.560 10.1093/jn/137.3.718S 10.1016/j.metabol.2005.01.031 10.1161/01.CIR.88.2.523 10.1172/JCI117936 10.1152/physrev.00047.2003 10.1093/jn/135.8.1911 10.1016/j.fct.2007.06.029 10.1016/S0140-6736(08)60804-1 10.1271/bbb.59.595 10.1079/BJN20051502 10.1161/01.CIR.0000129501.88485.1f 10.1093/jn/137.11.2405 10.1093/jn/135.10.2399 10.1093/jn/128.3.593 10.1161/01.HYP.0000150859.47929.8e 10.1093/ajcn/87.3.778 10.1080/10715760600823128 10.1016/j.jcrc.2005.02.002 10.1093/ajcn/84.1.252 10.1016/0891-5849(93)90027-R 10.1007/BF02536175 10.1093/ajcn/81.1.243S |
| ContentType | Journal Article |
| Copyright | Copyright © The Authors 2009 2009 INIST-CNRS |
| Copyright_xml | – notice: Copyright © The Authors 2009 – notice: 2009 INIST-CNRS |
| DBID | FBQ BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QP 7RV 7T5 7X2 7X7 7XB 88E 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ATCPS AZQEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9. KB0 M0K M0S M1P M2O MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI Q9U 7S9 L.6 7X8 8FD FR3 P64 RC3 |
| DOI | 10.1017/S0007114509359127 |
| DatabaseName | AGRIS Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Immunology Abstracts Agricultural Science Collection ProQuest Health & Medical Collection (NC LIVE) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland British Nursing Database (Proquest) Agricultural & Environmental Science Collection ProQuest Central Essentials ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Agricultural Science Database ProQuest Health & Medical Collection Medical Database Research Library Research Library (Corporate) ProQuest Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic AGRICOLA AGRICOLA - Academic MEDLINE - Academic Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts Genetics Abstracts |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest One Academic Eastern Edition Agricultural Science Collection British Nursing Index with Full Text ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) AGRICOLA AGRICOLA - Academic MEDLINE - Academic Genetics Abstracts Engineering Research Database Technology Research Database Biotechnology and BioEngineering Abstracts |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Genetics Abstracts CrossRef AGRICOLA Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database – sequence: 4 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Diet & Clinical Nutrition |
| DocumentTitleAlternate | S. Egert et al. Quercetin and CVD risk biomarkers |
| EISSN | 1475-2662 |
| EndPage | 1074 |
| ExternalDocumentID | 1914174561 19402938 21984523 10_1017_S0007114509359127 ark_67375_6GQ_V8H4K2HP_M US201301697472 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -E. -~X .FH 09C 09E 0E1 0R~ 23N 2WC 3EH 3V. 4.4 5GY 5RE 5VS 6J9 6PF 74X 74Y 7RV 7X2 7X7 7~V 88E 8C1 8FE 8FH 8FI 8FJ 8G5 8R4 8R5 9M5 AAAZR AABES AABWE AACJH AAFWJ AAGFV AAHBH AAIKC AAKTX AAMNQ AAMNW AARAB AASVR AATID AATMM AAUIS AAUKB AAWTL AAZAQ ABBJB ABBXD ABFBI ABGDZ ABJNI ABKKG ABKMT ABMWE ABQTM ABROB ABUWG ABVKB ABVZP ABWCF ABXAU ABZCX ABZUI ACBEK ACBMC ACDLN ACGFS ACIMK ACPRK ACRPL ACUIJ ACYZP ACZBM ACZUX ACZWT ADAZD ADBBV ADDNB ADFEC ADFRT ADKIL ADNMO ADVJH AEBAK AEHGV AEMFK AEMTW AENEX AENGE AEPLO AEUYN AEYHU AEYYC AFFUJ AFKQG AFKRA AFLOS AFLVW AFOSN AFRAH AFRIC AFUTZ AFZFC AGABE AGJUD AHIPN AHLTW AHMBA AHQXX AHRGI AIGNW AIHIV AIOIP AISIE AJ7 AJCYY AJPFC AJQAS ALMA_UNASSIGNED_HOLDINGS ALWZO AN0 ANPSP AQJOH ATCPS ATUCA AUXHV AZGZS AZQEC BAWUL BBLKV BENPR BHPHI BKEYQ BLZWO BNQBC BPHCQ BQFHP BRIRG BVXVI C0O C1A CAG CBIIA CCPQU CCQAD CFAFE CHEAL CJCSC COF CS3 DIK DOHLZ DU5 DWQXO E3Z EBS EJD EX3 F5P FYUFA GNUQQ GUQSH HCIFZ HG- HH5 HMCUK HZ~ I.6 IH6 IOEEP IOO IS6 I~P J36 J38 J3A JHPGK JKPOH JQKCU JVRFK KCGVB KFECR L7B L98 LW7 M-V M0K M1P M2O M7~ NAPCQ NIKVX O9- OK1 OVD P6G PCD PQQKQ PROAC PSQYO Q2X RAMDC RCA RIG ROL RR0 S6- S6U SAAAG SJN SY4 T9M TEORI TR2 UCJ UKHRP UT1 UU6 WFFJZ WH7 WOW WQ3 WXU WYP Y6R ZMEZD ZYDXJ ~KM -1D -1F -2P -2V -~6 -~N .55 .GJ 354 3O- 53G 6~7 AAEED AANRG AAYJJ ABBZL ABVFV ACCHT ACETC ACQFJ ACREK ACUYZ ACWGA ADGEJ ADOCW ADOVH ADOVT AEBPU AENCP AEQTP AFFNX AGLWM AGOOT AI. AKZCZ ALEEW ARABE ARZZG AYIQA BCGOX BESQT BGHMG BJBOZ BMAJL CCUQV CDIZJ CFBFF CGQII EGQIC FBQ HST I.7 I.9 KAFGG KC5 LHUNA M8. NMFBF NZEOI OHT UAP VH1 WXY X7M ZA5 ZCG ZDLDU ZGI ZJOSE ZXP ~V1 ABXHF AGQPQ AKMAY BSCLL PHGZM PHGZT PJZUB PPXIY PUEGO AAYXX CITATION AAKNA ACEJA ACOZI ANOYL IQODW CGR CUY CVF ECM EIF NPM 7QP 7T5 7XB 8FK H94 K9. MBDVC PKEHL PQEST PQUKI Q9U 7S9 L.6 7X8 8FD FR3 P64 RC3 |
| ID | FETCH-LOGICAL-c569t-5eec558049bcfb8fea5525a124c326ecc7581207264a8ce2cad151aa35c283203 |
| IEDL.DBID | 7X7 |
| ISSN | 0007-1145 1475-2662 |
| IngestDate | Mon Jul 21 11:00:45 EDT 2025 Thu Jul 10 21:59:33 EDT 2025 Fri Jul 11 05:22:07 EDT 2025 Sat Aug 23 13:28:26 EDT 2025 Mon Jul 21 05:56:23 EDT 2025 Mon Jul 21 09:14:49 EDT 2025 Tue Jul 01 03:50:00 EDT 2025 Thu Apr 24 22:59:31 EDT 2025 Sun Aug 31 06:49:29 EDT 2025 Wed Dec 27 19:13:51 EST 2023 Tue Jan 21 06:23:02 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | CVD Blood pressure Inflammation Oxidised LDL Quercetin Human Systolic pressure High risk Cardiovascular disease Concentration Blood plasma Overweight Lipoprotein LDL Vertebrata Phenotype Mammalia Double blind study Hemodynamics |
| Language | English |
| License | https://www.cambridge.org/core/terms CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c569t-5eec558049bcfb8fea5525a124c326ecc7581207264a8ce2cad151aa35c283203 |
| Notes | http://dx.doi.org/10.1017/S0007114509359127 istex:C8070BA7CA4B884593A3A14AB62550E121C7D935 Abbreviations: CRP, C-reactive protein; DBP, diastolic blood pressure; hs, high-sensitivity; SBP, systolic blood pressure ark:/67375/6GQ-V8H4K2HP-M PII:S0007114509359127 ArticleID:35912 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.cambridge.org/core/services/aop-cambridge-core/content/view/8DB47B7FB4C09E5D3995A2F3F577D473/S0007114509359127a.pdf/div-class-title-quercetin-reduces-systolic-blood-pressure-and-plasma-oxidised-low-density-lipoprotein-concentrations-in-overweight-subjects-with-a-high-cardiovascular-disease-risk-phenotype-a-double-blinded-placebo-controlled-cross-over-study-div.pdf |
| PMID | 19402938 |
| PQID | 213829449 |
| PQPubID | 5629 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_744613831 proquest_miscellaneous_734062771 proquest_miscellaneous_46474026 proquest_journals_213829449 pubmed_primary_19402938 pascalfrancis_primary_21984523 crossref_primary_10_1017_S0007114509359127 crossref_citationtrail_10_1017_S0007114509359127 istex_primary_ark_67375_6GQ_V8H4K2HP_M fao_agris_US201301697472 cambridge_journals_10_1017_S0007114509359127 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2009-10-14 |
| PublicationDateYYYYMMDD | 2009-10-14 |
| PublicationDate_xml | – month: 10 year: 2009 text: 2009-10-14 day: 14 |
| PublicationDecade | 2000 |
| PublicationPlace | Cambridge, UK |
| PublicationPlace_xml | – name: Cambridge, UK – name: Cambridge – name: England |
| PublicationTitle | British journal of nutrition |
| PublicationTitleAlternate | Br J Nutr |
| PublicationYear | 2009 |
| Publisher | Cambridge University Press |
| Publisher_xml | – name: Cambridge University Press |
| References | S0007114509359127_ref17 S0007114509359127_ref16 S0007114509359127_ref38 S0007114509359127_ref19 S0007114509359127_ref18 S0007114509359127_ref35 S0007114509359127_ref12 S0007114509359127_ref34 S0007114509359127_ref15 S0007114509359127_ref37 S0007114509359127_ref36 S0007114509359127_ref14 S0007114509359127_ref31 S0007114509359127_ref30 S0007114509359127_ref11 S0007114509359127_ref33 S0007114509359127_ref10 S0007114509359127_ref32 Boesch-Saadatmandi (S0007114509359127_ref39) 2008 S0007114509359127_ref9 S0007114509359127_ref7 S0007114509359127_ref8 Theriault (S0007114509359127_ref48) 2000; 41 S0007114509359127_ref28 S0007114509359127_ref27 (S0007114509359127_ref13) 2000 S0007114509359127_ref24 S0007114509359127_ref46 S0007114509359127_ref45 S0007114509359127_ref23 S0007114509359127_ref26 S0007114509359127_ref25 S0007114509359127_ref47 S0007114509359127_ref1 S0007114509359127_ref20 S0007114509359127_ref42 S0007114509359127_ref2 S0007114509359127_ref41 S0007114509359127_ref44 S0007114509359127_ref22 S0007114509359127_ref43 S0007114509359127_ref21 S0007114509359127_ref5 S0007114509359127_ref6 S0007114509359127_ref3 S0007114509359127_ref40 S0007114509359127_ref4 Holvoet (S0007114509359127_ref29) 2008; 70 |
| References_xml | – ident: S0007114509359127_ref34 doi: 10.1038/oby.2008.315 – ident: S0007114509359127_ref23 doi: 10.1093/ajcn/88.4.1018 – ident: S0007114509359127_ref41 doi: 10.1093/ajcn/70.6.1040 – ident: S0007114509359127_ref32 doi: 10.1074/jbc.M706571200 – ident: S0007114509359127_ref6 doi: 10.1093/ajcn/88.1.38 – ident: S0007114509359127_ref7 doi: 10.1017/S1462399403006732 – ident: S0007114509359127_ref4 doi: 10.1007/PL00007376 – volume: 41 start-page: 1969 year: 2000 ident: S0007114509359127_ref48 article-title: Modulation of hepatic lipoprotein synthesis and secretion by taxifolin, a plant flavonoid publication-title: J Lipid Res doi: 10.1016/S0022-2275(20)32358-0 – ident: S0007114509359127_ref33 doi: 10.1128/CVI.13.3.319-328.2006 – ident: S0007114509359127_ref10 doi: 10.1038/sj.ijo.0802756 – ident: S0007114509359127_ref26 doi: 10.1074/jbc.M606804200 – ident: S0007114509359127_ref12 doi: 10.1093/jn/135.9.2257 – ident: S0007114509359127_ref18 doi: 10.1001/jama.289.19.2560 – ident: S0007114509359127_ref31 doi: 10.1021/jf8003042 – ident: S0007114509359127_ref28 doi: 10.2337/diabetes.53.4.1068 – ident: S0007114509359127_ref9 doi: 10.1093/jn/138.9.1615 – ident: S0007114509359127_ref16 doi: 10.1093/jn/138.8.1417 – ident: S0007114509359127_ref43 doi: 10.1093/ajcn/81.1.122 – ident: S0007114509359127_ref36 doi: 10.1093/ajcn/78.6.1135 – ident: S0007114509359127_ref17 doi: 10.1002/sim.4780060806 – ident: S0007114509359127_ref38 doi: 10.1016/j.nut.2008.03.023 – ident: S0007114509359127_ref3 doi: 10.1007/BF01617836 – year: 2008 ident: S0007114509359127_ref39 article-title: Effect of apoE genotype and dietary quercetin on blood lipids and TNF-α levels in apoE3 and apoE4 targeted gene replacement mice publication-title: Br J Nutr – ident: S0007114509359127_ref2 doi: 10.1093/ajcn/76.3.560 – ident: S0007114509359127_ref1 doi: 10.1093/jn/137.3.718S – ident: S0007114509359127_ref30 doi: 10.1016/j.metabol.2005.01.031 – ident: S0007114509359127_ref25 doi: 10.1161/01.CIR.88.2.523 – ident: S0007114509359127_ref35 doi: 10.1172/JCI117936 – ident: S0007114509359127_ref27 doi: 10.1152/physrev.00047.2003 – ident: S0007114509359127_ref47 doi: 10.1093/jn/135.8.1911 – ident: S0007114509359127_ref8 doi: 10.1016/j.fct.2007.06.029 – ident: S0007114509359127_ref21 doi: 10.1016/S0140-6736(08)60804-1 – ident: S0007114509359127_ref44 doi: 10.1271/bbb.59.595 – ident: S0007114509359127_ref40 doi: 10.1079/BJN20051502 – volume-title: Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series no. 894 year: 2000 ident: S0007114509359127_ref13 – ident: S0007114509359127_ref22 doi: 10.1161/01.CIR.0000129501.88485.1f – ident: S0007114509359127_ref20 doi: 10.1093/jn/137.11.2405 – ident: S0007114509359127_ref37 doi: 10.1093/jn/135.10.2399 – ident: S0007114509359127_ref19 doi: 10.1093/jn/128.3.593 – ident: S0007114509359127_ref14 doi: 10.1161/01.HYP.0000150859.47929.8e – ident: S0007114509359127_ref42 doi: 10.1093/ajcn/87.3.778 – ident: S0007114509359127_ref24 doi: 10.1080/10715760600823128 – ident: S0007114509359127_ref11 doi: 10.1016/j.jcrc.2005.02.002 – volume: 70 start-page: 193 year: 2008 ident: S0007114509359127_ref29 article-title: Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease publication-title: Verh K Acad Geneeskd Belg – ident: S0007114509359127_ref46 doi: 10.1093/ajcn/84.1.252 – ident: S0007114509359127_ref15 doi: 10.1016/0891-5849(93)90027-R – ident: S0007114509359127_ref45 doi: 10.1007/BF02536175 – ident: S0007114509359127_ref5 doi: 10.1093/ajcn/81.1.243S |
| SSID | ssj0008109 |
| Score | 2.489702 |
| Snippet | Regular consumption of flavonoids may reduce the risk for CVD. However, the effects of individual flavonoids, for example, quercetin, remain unclear. The... |
| SourceID | proquest pubmed pascalfrancis crossref istex fao cambridge |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1065 |
| SubjectTerms | Adult adults adverse effects Aged Anthropometry Anthropometry - methods Antioxidants Antioxidants - adverse effects Antioxidants - pharmacology Biological and medical sciences blood Blood Glucose Blood Glucose - metabolism blood lipids Blood Pressure Blood Pressure - drug effects Body Composition Body Composition - drug effects Body Weight Body Weight - drug effects Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention & control Cholesterol complications CVD Diet Dietary Supplements drug effects Epidemiologic Methods etiology Feeding. Feeding behavior Female Flavonoids Fundamental and applied biological sciences. Psychology Health risks Heart Rate Heart Rate - drug effects Human and Clinical Nutrition Humans Inflammation Inflammation Mediators Inflammation Mediators - blood Lipids Lipids - blood Lipoproteins, LDL Lipoproteins, LDL - blood Low density lipoprotein Male Metabolic disorders metabolic syndrome metabolism methods Middle Aged Nutrition research Nutritional status Obesity overweight Overweight - blood Overweight - complications Overweight - physiopathology Oxidative stress Oxidised LDL Patient Compliance pharmacology Phenotype physiopathology placebo-controlled cross-over study placebos prevention & control Quercetin Quercetin - adverse effects Quercetin - pharmacology risk factors systolic blood pressure Uric Acid Uric Acid - blood Vertebrates: anatomy and physiology, studies on body, several organs or systems Waist Circumference Waist Circumference - drug effects |
| Title | Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study |
| URI | https://www.cambridge.org/core/product/identifier/S0007114509359127/type/journal_article https://api.istex.fr/ark:/67375/6GQ-V8H4K2HP-M/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/19402938 https://www.proquest.com/docview/213829449 https://www.proquest.com/docview/46474026 https://www.proquest.com/docview/734062771 https://www.proquest.com/docview/744613831 |
| Volume | 102 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1db9MwFLXY9sIL4nthUPyA9oBm0Th24vCCYGxUoFUbUNS3yHEcVBGS0qRi_F9-CPe6bqoKrS-Vmtpu6hzb9-P0XEJelCkvtYEnIIs0Z0KlBVM5T1hS5EWq-VBaF8y5GMejifg4lVPPzWk9rXK9J7qNumgMxshfcRTLS4VI38x_MSwahclVX0FjjxygchmCOpn2_hYcdp7hgTqIoZDrpKZTjMazFa5hHjB1NWU20gpbR9ReqRswXHHOr5E4qVuYu3JV9OJmq9SdTud3yR1vVtK3KxzcI7dsfZ8E72e2o8fUa39WdLyW3n9A_l4tkdLSzWq6QPVW21IUdUaVYOrI7NQxZJcLS3UNb8DI_qlpcz3DjE5Bq-Y3K5D73v2h1WzeOLkHGMvgvyBrL8XbUrjSOOY1hgBou8wx6tNSDP5STVEqmZktQiz1CSOKlHeK_LMGg8SvoXXRLPPKsrxCgcfihDo2Wd4wT7av4K7cfDL8Rupkcx-SyfnZ19MR8xUfmJFx2jFprZFSgdeSmzJXpdVScqnBBjFgZgLawLsJ-TABK04rY7nRBVgsWkfSYMmlYfSI7NdNbQ8JFWFZ6jDR4OFboWMLwFMFDwF6YZToVAXkpH_gmV-3bbbivCXZf_gIyHCNicx49XQs4lHt6vKy7zJfSYfsanwIQMv0d5jebPKFY0I5jNHZ4wE5dujrB9GLH0jHS2QWf7jKvqmR-MRHl9lFQAZb8Ow7wKmkhORRQI7WeN385H5hBeR5_ynsMZg40rVtlm0mYpEIcNYDQm9okUQC9a6TcEcTIcB0VBE0ebxaKptZSWH0NFJPdt7fEbntUnlIJxJPyX63WNpnYBF2-cCte3hVp-GAHLw7G19-_gcf3mBn |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELe28QAviP8Lg-0eYA9oEY1jJw4SQmhjdHStmNjQ3jIncVBFSErTatuH4lvxQbhzk1YVWt_22NR2Evt8d7n7-XeMvcojnusUV0BmUeIKFWWuSnjohlmSRZp3pLHBnP4g6J6JL-fyfI39ac_CEKyy1YlWUWdVSjHyt5zI8iIhog-j3y4VjaLkaltBYyYVPXN9iV9s9fujA1ze15wffjrd77pNUQE3lUE0caUxqZQKHeMkzROVGy0llxrNXIqeDL4QOtAe74ToKGiVGp7qDI2i1r5MqapPx8dx19kd4ePOpIPp-wtEifIaRAnxLnpCtklUy1BNthyvUd4xsjVsFlQOSyZxPdcVOsq0xlcE1NQ1rlU-K7JxsxdsreHhA3a_cWPh40zuHrI1Uz5izsHQTGAXGq7RAgYt1f9j9vdkShCaybCEMbHFmhqIRJpYicGC58EicqdjA7rEH-jU_9JQXQ0pg5RBUV26GWHtJ9dQDEeVpZfAsVI6dVk21L814JXKIr0p5AD1NKEoUw0UbAYNRM3spksAXGgSVEAQeyC8W0VB6XfYOqumSWHcpCBCyWwPLHotqdwG3F_gU9n5dOmOYGl6n7CzWxGGp2yjrEqzyUB4ea69UCuljNCBQUFXGfdQ1D0_1JFy2N58weNGT9TxDGMXxv_Jh8M6rUzEacPWTkVDilVd3sy7jGZUJasab6KgxfoHTm989o1TAtsL6OOSO2zXSt98ED3-SfC_UMbB55P4u-qKHu9-jfsO214Sz3kHtIJKSO47bKuV18Urzzeyw3bm_6JOo0SVLk01rWMRiFB0eOAwuKFF6Avi1w69FU2EQFdV-djk2WyrLGYlwtEjXz1f-Xw77G73tH8cHx8Nelvsnk0jEpRJvGAbk_HUvERvdJJsWx0A7OK2lc4_fzGaUQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb5RAEN-0NTG-GP8Xq-08aB9MSY9lFxYTY0xrvXq2aaM1faMLLOYiwnncpe1H8_v4QZxZ4C4X03vrI7C7wO7szDDz4zeMvcojnusUV0BmUeIKFWWuSnjohlmSRZr3pLHBnKPjoH8mPp_L8xX2p_sXhmCVnU60ijqrUoqR73Iiy4uEiHbzFhVxsn_wfvTbpQJSlGjtqmk0EjIw15f49Va_O9zHpX7N-cHHb3t9ty0w4KYyiCauNCaVUqGTnKR5onKjpeRSo8lL0avBl0Nn2uO9EJ0GrVLDU52hgdTalylV-On5OO4quxP6oaItpvbm6BLltegS4mD0hOwSqpatmuw6nqMcZGTr2cxpHRbM42quK3Saab2vCLSpa1y3vCm4cbNHbC3jwQN2v3Vp4UMjgw_ZiikfMWd_aCawDS3vaAHHHe3_Y_b3dEpwmsmwhDExx5oaiFCaGIrBAunBonOnYwO6xAN08H9pqK6GlE3KoKgu3Yxw95NrKIajylJN4Fgp_YFZtjTANeCZyqK-KfwA9TShiFMNFHgGDUTT7KYLYFxok1VAcHsg7FtFAeq32Dqrpklh3KQgcslsByySLancFuhf4FPZ-XTpjmApe5-ws1sRhqdsraxKs85AeHmuvVArpYzQgUGhVxn3UOw9P9SRctjObMHjVmfUcYO3C-P_5MNhvU4m4rRlbqcCIsWyLm9mXUYNbcmyxusoaLH-gdMbn33llMz2AvrQ5A7bttI3G0SPfxIUMJRx8Ok0_q76YsD7J_GRwzYXxHPWAS2iEpL7Dtvo5HX-yrNN7bCt2VXUb5S00qWppnUsAhGKHg8cBje0CH1BXNuht6SJEOi2Kh-bPGu2ynxWIhw98tXzpc-3xe6iuom_HB4PNtg9m1EkVJN4wdYm46l5iY7pJNm0KgDYxW3rnH_0Pp6H |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quercetin+reduces+systolic+blood+pressure+and+plasma+oxidised+low-density+lipoprotein+concentrations+in+overweight+subjects+with+a+high-cardiovascular+disease+risk+phenotype%3A+a+double-blinded%2C+placebo-controlled+cross-over+study&rft.jtitle=British+journal+of+nutrition&rft.au=Egert%2C+Sarah&rft.au=Bosy-Westphal%2C+Anja&rft.au=Seiberl%2C+Jasmin&rft.au=K%C3%BCrbitz%2C+Claudia&rft.date=2009-10-14&rft.pub=Cambridge+University+Press&rft.issn=0007-1145&rft.eissn=1475-2662&rft.volume=102&rft.issue=7&rft.spage=1065&rft.epage=1074&rft_id=info:doi/10.1017%2FS0007114509359127&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_6GQ_V8H4K2HP_M |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1145&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1145&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1145&client=summon |